Federal Lawsuit Challenges Medicare's Unprecedented Move to Fund Unapproved Cannabis
Washington D.C., Saturday, 25 April 2026.
A landmark lawsuit challenges a new Medicare program that bypasses FDA safety reviews to distribute unapproved cannabis products, potentially reshaping federal healthcare and pharmaceutical regulations.
The Legal Challenge to Medicare’s New Pathway
On April 25, 2026, plaintiffs filed a significant motion in the U.S. District Court for the District of Columbia, seeking an immediate injunction to block the Centers for Medicare & Medicaid Services (CMS) from continuing its Substance Access Beneficiary Engagement Incentive (BEI) program [7]. Launched on April 1, 2026, by CMS Administrator Mehmet Oz, the BEI program operates as a federally supported pilot initiative allowing doctors to recommend hemp-derived CBD products to Medicare seniors, providing up to $500 per year in coverage [1][2]. However, the lawsuit, spearheaded by pharmaceutical cannabinoid developer MMJ International Holdings, alleges that the agency unlawfully introduced these consumer products into the Medicare delivery system without adhering to the Administrative Procedure Act’s formal public rulemaking and notice-and-comment procedures [1][4].
Conflicting Federal Standards and Market Disruption
Beyond procedural concerns, the BEI program introduces glaring contradictions within federal policy. Under the CMS pilot, beneficiaries are permitted access to intoxicating hemp products containing up to 3 milligrams of total THC per serving [2]. This limit directly conflicts with the impending 2026 Agriculture Appropriations Act, which is scheduled to implement a strict federal ban in November 2026 [1][2]. The forthcoming law restricts intoxicating hemp products to no more than 0.4 milligrams of total THC per container [1][2]. Consequently, the CMS program authorizes a per-serving THC limit that is 7.5 times greater than the total container limit mandated by the upcoming November legislation [1][2]. Furthermore, the plaintiffs noted in an April 24, 2026, reply brief that CMS itself acknowledged in its Contract Year 2027 final rule that it “does not regulate cannabis and hemp-derived cannabis products” [1].
Political Maneuvering and Rescheduling Efforts
The CMS controversy unfolds against a backdrop of aggressive political maneuvering regarding cannabis regulation. In December 2025, President Donald Trump issued an Executive Order directing his administration to find a regulatory pathway for safe access to nonintoxicating, full-spectrum CBD products and to reclassify cannabis [2][3]. This culminated in actual policy implementation on April 22, 2026, when the Acting Attorney General issued a final order placing specific categories of marijuana into Schedule III of the Controlled Substances Act [3]. However, this rescheduling is narrowly tailored; it strictly applies only to FDA-approved marijuana drug products and marijuana subject to state-issued medical licenses, leaving recreational marijuana, synthetically derived THC, and unlicensed bulk materials as Schedule I substances [3].
Future Regulatory Implications for Healthcare
The immediate future of cannabinoid regulation remains highly fluid, with several critical deadlines approaching. State-licensed medical marijuana operators impacted by the April 22 rescheduling have an expedited 60-day window, closing on June 22, 2026, to submit Drug Enforcement Administration (DEA) registration applications to continue operating under state licenses during the federal review period [3]. Shortly thereafter, the DEA is scheduled to commence a hearing on June 29, 2026, to evaluate broader changes to the federal status of marijuana [3]. Meanwhile, the looming implementation of the Agriculture Appropriations Act in November 2026 casts uncertainty over spring planting decisions recently made by American hemp farmers [2].